Magnetic resonance image features identify glioblastoma phenotypic subtypes with distinct molecular pathway activities

Science Translational Medicine

Volumn 7, Issue 303, 2015, Pages

  Itakura, Haruka ^a   Achrol, Achal S ^b   Mitchell, Lex A ^b   Loya, Joshua J ^b   Liu, Tiffany ^a   Westbroek, Erick M ^c   Feroze, Abdullah H ^b   Rodriguez, Scott ^b   Echegaray, Sebastian ^d   Azad, Tej D ^b   Yeom, Kristen W ^b   Napel, Sandy ^b   Rubin, Daniel L ^a,b   Chang, Steven D ^b   Harsh, Griffith R ^b   Gevaert, Olivier ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d Stanford University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AREA UNDER THE CURVE; ARTICLE; COHORT ANALYSIS; FEMALE; GENE DOSAGE; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; BRAIN TUMOR; CLASSIFICATION; PATHOLOGY; VALIDATION STUDY;

BRAIN NEOPLASMS; COHORT STUDIES; GLIOBLASTOMA; MAGNETIC RESONANCE IMAGING;

EID: 84940833109     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aaa7582     Document Type: Article

References (47)

1. S. M. Chang, I. F. Parney, W. Huang, F. A. Anderson Jr., A. L. Asher, M. Bernstein, K. O. Lillehei, H. Brem, M. S. Berger, E. R. Laws; Glioma Outcomes Project Investigators, Patterns of care for adults with newly diagnosed malignant glioma. JAMA 293, 557-564 (2005).
2. Vanderbilt-Ingram Cancer Center, "3T MRI Biomarkers of Glioma Treatment Response, " ClinicalTrials.gov (Vanderbilt-Ingram Cancer Center, National Cancer Institute, 2013).
3. Massachusetts General Hospital, "Bevacizumab with temozolomide PET and vascular MRI for GBM, " ClinicalTrials.gov (Massachusetts General Hospital, 2013).
4. E. R. Laws, I. F. Parney, W. Huang, F. Anderson, A. M. Morris, A. Asher, K. O. Lillehei, M. Bernstein, H. Brem, A. Sloan, M. S. Berger, S. Chang; Glioma Outcomes Investigators, Survival following surgery and prognostic factors for recently diagnosed malignant glioma: Data from the Glioma Outcomes Project. J. Neurosurg. 99, 467-473 (2003).
5. 6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J. Clin. Oncol. 26, 4189-4199 (2008).
6. H. Yan, D. W. Parsons, G. Jin, R. McLendon, B. A. Rasheed, W. Yuan, I. Kos, I. Batinic-Haberle, S. Jones, G. J. Riggins, H. Friedman, A. Friedman, D. Reardon, J. Herndon, K. W. Kinzler, V. E. Velculescu, B. Vogelstein, D. D. Bigner, IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360, 765-773 (2009).
7. M. Sanson, Y. Marie, S. Paris, A. Idbaih, J. Laffaire, F. Ducray, S. El Hallani, B. Boisselier, K. Mokhtari, K. Hoang-Xuan, J.-Y. Delattre, Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J. Clin. Oncol. 27, 4150-4154 (2009).
8. R. G. W. Verhaak, K. A. Hoadley, E. Purdom, V. Wang, Y. Qi, M. D. Wilkerson, C R. Miller, L. Ding, T. Golub, J. P. Mesirov, G. Alexe, M. Lawrence, M. O'Kelly, P. Tamayo, B. A. Weir, S. Gabrie, W. Winckler, S. Gupta, L. Jakkula, H. S. Feiler, J. G. Hodgson, C. D. James, J. N. Sarkaria, C. Brennan, A. Kahn, P.T. Spellman, R. K. Wilson, T. P. Speed, J. W. Gray, M. Meyerson, G. Getz, C. M. Perou, D. N. Hayes; Cancer Genome Atlas Research Network, Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17, 98-110 (2010).
9. D. A. Haas-Kogan, M. D. Prados, T.Tihan, D. A. Eberhard, N.Jelluma, N. D. Arvold, R. Baumber, K. R. Lamborn, A. Kapadia, M. Malec, M. S. Berger, D. Stokoe, Epidermal growthfactor receptor, protein kinase B/Akt, and glioma response to erlotinib. J. Natl. Cancer Inst. 97, 880-887 (2005).
10. H. Noushmehr, D. J. Weisenberger, K. Diefes, H. S. Phillips, K. Pujara, B. P. Berman, F. Pan, C. E. Pelloski, E. P. Sulman, K. P. Bhat, R. G. W. Verhaak, K. A. Hoadley, D. N. Hayes, C. M. Perou, H. K. Schmidt, L. Ding, R. K. Wilson, D. Van Den Berg, H. Shen, H. Bengtsson, P. Neuvial, L. M. Cope, J. Buckley, J. G. Herman, S. B. Baylin, P. W. Laird, K. Aldape; Cancer Genome Atlas Research Network, Identification of a CpG island methylator phenotypethat defines a distinct subgroup of glioma. Cancer Cell 17, 510-522 (2010).
11. M. Bredel, D. M. Scholtens, G. R. Harsh, C Bredel, J. P. Chandler, J. J. Renfrow, A. K. Yadav, H. Vogel, A. C. Scheck, R. Tibshirani, B. I. Sikic, A network model of a cooperative genetic landscape in brain tumors. JAMA 302, 261-275 (2009).
12. D. Sturm, H. Witt, V. Hovestadt, D.-A. Khuong-Quang, D. T. W. Jones, C. Konermann, E. Pfaff, M. Tönjes, M. Sill, S. Bender, M. Kool, M. Zapatka, N. Becker, M. Zucknick, T. Hielscher, X.-Y. Liu, A. M. Fontebasso, M. Ryzhova, S. Albrecht, K. Jacob, M.Wolter, M. Ebinger, M. U.Schuhmann, T. van Meter, M. C Frühwald, H. Hauch, A. Pekrun, B. Radlwimmer, T. Niehues, G. von Komorowski, M. Dürken, A. E. Kulozik, J. Madden, A. Donson, N. K. Foreman, R. Drissi, M. Fouladi, W. Scheurlen, A. von Deimling, C. Monoranu, W. Roggendorf, C. Herold-Mende, A. Unterberg, C. M. Kramm, J. Felsberg, C Hartmann, B. Wiestler, W. Wick, T. Milde, O. Witt, A. M. Lindroth, J. Schwartzentruber, D. Faury, A. Fleming, M. Zakrzewska, P. P. Liberski, K. Zakrzewski, P. Hauser, M. Garami, A. Klekner, L. Bognar, S. Morrissy, F. Cavalli, M. D.Taylor, P. van Sluis, J. Koster, R.Versteeg, R. Volckmann, T. Mikkelsen, K. Aldape, G. Reifenberger, V. P. Collins, J. Majewski, A. Korshunov, P. Lichter, C Plass, N. Jabado, S. M. Pfister, Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 22, 425-437 (2012).
13. A. Sottoriva, I. Spiteri, S. G. M. Piccirillo, A.Touloumis, V. P. Collins, J. C. Marioni, C. Curtis, C. Watts, S. Tavaré, Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc. Natl. Acad. Sci. USA. 110, 4009-4014 (2013).
14. A. P. Patel, I. Tirosh, J. J. Trombetta, A. K. Shalek, S. M. Gillespie, H. Wakimoto, D. P. Cahill, B. V. Nahed, W. T. Curry, R. L. Martuza, D. N. Louis, O. Rozenblatt-Rosen, M. L. Suvà, A. Regev, B. E. Bernstein, Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344, 1396-1401 (2014).
15. O. Gevaert, L. A. Mitchell, A. S. Achrol, J. Xu, S. Echegaray, G. K. Steinberg, S. H. Cheshier, S. Napel, G. Zaharchuk, S. K. Plevritis, Glioblastoma multiforme: Exploratory radiogenomic analysis by using quantitative image features. Radiology 276, 313 (2015).
16. D. A. Gutman, L. A. D. Cooper, S. N. Hwang, C. A. Holder, J. Gao, T. D. Aurora, W. D. Dunn Jr., L. Scarpace, T. Mikkelsen, RJain, M. Wintermark, M.Jilwan, P. Raghavan, E. Huang, R. J. Clifford, P. Mongkolwat, V. Kleper, J. Freymann, J. Kirby, P. O. Zinn, C. S. Moreno, C. Jaffe, R. Colen, D. L. Rubin, J. Saltz, A. Flanders, D. J. Brat, MR imaging predictors of molecular profile and survival: Multi-institutional study of the TCGA glioblastoma data set Radiology 267, 560-569 (2013).
17. M. Diehn, C. Nardini, D. S.Wang, S. McGovern, M. Jayaraman, Y. Liang, K. Aldape, S. Cha, M. D. Kuo, Identification of noninvasive imaging surrogates for brain tumor gene-expression modules. Proc. Natl. Acad. Sci. US.A. 105, 5213-5218 (2008).
18. B. M. Ellingson, A. Lai, R. J. Harris, J. M. Selfridge, W. H.Yong, K. Das, W. B. Pope, P. L. Nghiemphu, H. V. Vinters, L. M. Liau, P. S. Mischel, T. F. Cloughesy, Probabilistic radiographic atlas of glioblastoma phenotypes. AJNR Am. J. Neuroradiol. 34, 533-540 (2013).
19. O. Gevaert, J. Xu, C. D. Hoang, A. N. Leung, Y. Xu, A. Quon, D. L. Rubin, S. Napel, S. K. Plevritis, Non-small cell lung cancer: Identifying prognostic imaging biomarkers by leveraging public gene expression microarray data-Methods and preliminary results. Radiology 264, 387-396 (2012)
20. 18F-FDG uptake imaging features are associated with major oncogenomic alterations in patients with resected non-small cell lung cancer. Cancer Res. 72, 3725-3734 (2012).
21. P. O. Zinn, B. Majadan, P. Sathyan, S. K. Singh, S. Majumder, F. A. Jolesz, R. R. Colen, Radio-genomic mapping of edema/cellular invasion MRI-phenotypes in Glioblastoma Multiforme. PLOS One 6, e25451 (2011).
22. V. G. Tusher, R. Tibshirani, G. Chu, Significance analysis of microarrays applied to the ionizing radiation response. Proc. Natl. Acad. Sci. U.S.A. 98, 5116-5121 (2001).
23. A. V. Kapp, R. Tibshirani, Are clusters found in one dataset present in another dataset? Biostatistics 8, 9-31 (2007).
24. R. Tibshirani, T. Hastie, B. Narasimhan, G. Chu, Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc. Natl. Acad. Sci. U.S.A. 99, 6567-6572 (2002).
25. R. Stupp, M. E. Hegi, W. P. Mason, M. J. van den Bent, M. J. B. Taphoorn, R. C. Janzer, S. K. Ludwin, A. Allgeier, B. Fisher, K. Belanger, P. Hau, A. A. Brandes, J. Gijtenbeek, C. Marosi, C. J. Vecht, K. Mokhtari, P. Wesseling, S. Villa, E. Eisenhauer, T. Gorlia, M. Weller, D. Lacombe, J. G. Cairncross, R.-O. Mirimanoff; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group, Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-Year analysis of the EORTC-NCIC trial. Lancet Oncol. 10, 459-466 (2009).
26. C. J. Vaske, S. C. Benz, J. Z. Sanborn, D. Earl, C. Szeto, J. Zhu, D. Haussler, J. M. Stuart, Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM. Bioinformatics 26, i237-i245 (2010).
27. D. R. Macdonald, T. L. Cascino, S. C. Schold Jr., J. G. Cairncross, Response criteria for phase II studies of supratentorial malignant glioma. J. Clin. Oncol. 8, 1277-1280 (1990).
28. P. Y. Wen, D. R. Macdonald, D. A. Reardon, T. F. Cloughesy, A. G. Sorensen, E. Galanis, J. DeGroot, W. Wick, M. R. Gilbert, A. B. Lassman, C. Tsien, T. Mikkelsen, E. T. Wong, M. C. Chamberlain, R. Stupp, K. R. Lamborn, M. A. Vogelbaum, M. J. van den Bent, S. M. Chang, Updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology Working Group. J. Clin. Oncol. 28, 1963-1972 (2010).
29. L. B. Nabors, M. Ammirati, P. J. Bierman, H. Brem, N. Butowski, M. C. Chamberlain, L. M. DeAngelis, R. A. Fenstermaker, A. Friedman, M. R. Gilbert, D. Hesser, M. Holdhoff, L. Junck, R. Lawson, J. S. Loeffler, M. H. Maor, P. L. Moots, T. Morrison, M. M. Mrugala, H. B. Newton, J. Portnow, J. J. Raizer, L. Recht, D. C. Shrieve, A. K. Sills Jr., D. Tran, N. Tran, F. D. Vrionis, P. Y. Wen, N. McMillian, M. Ho; National Comprehensive Cancer Network, Central nervous system cancers. J. Natl. Compr. Canc. Netw. 11, 1114-1151 (2013).
30. K. H. Plate, G. Breier, H. A. Weich, W. Risau, Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359, 845-848 (1992).
31. D. J. Hicklin, L. M. Ellis, Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol. 23, 1011-1027 (2005).
32. R. A. Berkman, M. J. Merrill, W. C. Reinhold, W. T. Monacci, A. Saxena, W. C. Clark, J. T. Robertson, I. U. Ali, E. H. Oldfield, Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms. J. Clin. Invest. 91, 153-159 (1993).
33. O. L. Chinot, T. de La Motte Rouge, N. Moore, A. Zeaiter, A. Das, H. Phillips, Z. Modrusan, T. Cloughesy, AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. Adv. Ther. 28, 334-340 (2011).
34. J. J. Vredenburgh, A. Desjardins, J. E. Herndon II, J. Marcello, D. A. Reardon, J. A. Quinn, J. N. Rich, S. Sathornsumetee, S. Gururangan, J. Sampson, M. Wagner, L. Bailey, D. D. Bigner, A. H. Friedman, H. S. Friedman, Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J. Clin. Oncol. 25, 4722-4729 (2007).
35. T. N. Kreisl, L. Kim, K. Moore, P. Duic, C. Royce, I. Stroud, N. Garren, M. Mackey, J. A. Butman, K. Camphausen, J. Park, P. S. Albert, H. A. Fine, Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J. Clin. Oncol. 27, 740-745 (2009).
36. A. Lai, A. Tran, P. L. Nghiemphu, W. B. Pope, O. E. Solis, M. Selch, E. Filka, W. H. Yong, P. S. Mischel, L. M. Liau, S. Phuphanich, K. Black, S. Peak, R. M. Green, C. E. Spier, T. Kolevska, J. Polikoff, L. Fehrenbacher, R. Elashoff, T. Cloughesy, Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multi-forme. J. Clin. Oncol. 29, 142-148 (2011).
37. A. Narayana, D. Gruber, S. Kunnakkat, J. G. Golfinos, E. Parker, S. Raza, D. Zagzag, P. Eagan, M. L. Gruber, A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma. J. Neurosurg. 116, 341-345 (2012).
38. T. Cascone, J. V. Heymach, Targeting the angiopoietin/Tie2 pathway: Cutting tumor vessels with a double-edged sword? J. Clin. Oncol. 30, 441-444 (2012).
39. O. L. Chinot, W. Wick, W. Mason, R. Henriksson, F. Saran, R. Nishikawa, A. F. Carpentier, K. Hoang-Xuan, P. Kavan, D. Cernea, A. A. Brandes, M. Hilton, L. Abrey, T. Cloughesy, Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N. Engl. J. Med. 370, 709-722 (2014).
40. H. Colman, L. Zhang, E. P. Sulman, J. M. McDonald, N. L. Shooshtari, A. Rivera, S. Popoff, C. L. Nutt, D. N. Louis, J. G. Cairncross, M. R. Gilbert, H. S. Phillips, M. P. Mehta, A. Chakravarti, C. E. Pelloski, K. Bhat, B. G. Feuerstein, R. B. Jenkins, K. Aldape, A multigene predictor of outcome in glioblastoma. Neuro Oncol. 12, 49-57 (2010).
41. M. D. Wilkerson, D. N. Hayes, ConsensusClusterPlus: A class discovery tool with confidence assessments and item tracking. Bioinformatics 26, 1572-1573 (2010).
42. S. Monti, P. Tamayo, J. Mesirov, T. Golub, Consensus clustering: A resampling-based method for class discovery and visualization of gene expression microarray data. Mach. Learn. 52, 91-118 (2003).
43. A. Agresti, Categorical Data Analysis (John Wiley & Sons, Hoboken, NJ, ed. 3, 2013).
44. J. H. McDonald, Handbook of Biological Statistics (Sparky House Publishing, Baltimore, MD, ed. 3, 2014).
45. K. R. Lamborn, S. M. Chang, M. D. Prados, Prognostic factors for survival of patients with glioblastoma: Recursive partitioning analysis. Neuro Oncol. 6, 227-235 (2004).
46. J. G. Scott, L. Bauchet, T. J. Fraum, L. Nayak, A. R. Cooper, S. T. Chao, J. H. Suh, M. A. Vogelbaum, D. M. Peereboom, S. Zouaoui, H. Mathieu-Daude, P. Fabbro-Peray, V. Rigau, L. Taillandier, L. E. Abrey, L. M. DeAngelis, J. H. Shih, F. M. Iwamoto, Recursive partitioning analysis of prognostic factors for glioblastoma patinets aged 70 years or older. Cancer 118, 5595-5600 (2012).
47. M. E. Hegi, A. C. Diserens, T. Gorlia, M. F. Hamou, N. de Tribolet, M. Weller, J. M. Kros, J. A. Hainfellner, W. Mason, L. Mariani, J. E. Bromberg, P. Hau, R. O. Mirimanoff, J. G. Cairncross, R. C. Janzer, R. Stupp, MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352, 997-1003 (2005).